[HTML][HTML] Anti-tuberculosis treatment strategies and drug development: challenges and priorities

VA Dartois, EJ Rubin - Nature Reviews Microbiology, 2022 - nature.com
Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

The treatment of tuberculosis

CA Peloquin, GR Davies - Clinical Pharmacology & …, 2021 - Wiley Online Library
Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a
major driver. Clinically, TB presents as “latent” TB and active TB disease, and the treatment …

A bacterial phospholipid phosphatase inhibits host pyroptosis by hijacking ubiquitin

Q Chai, S Yu, Y Zhong, Z Lu, C Qiu, Y Yu, X Zhang… - Science, 2022 - science.org
The inflammasome-mediated cleavage of gasdermin D (GSDMD) causes pyroptosis and
inflammatory cytokine release to control pathogen infection, but how pathogens evade this …

Types and functions of heterogeneity in mycobacteria

ES Chung, WC Johnson, BB Aldridge - Nature Reviews Microbiology, 2022 - nature.com
The remarkable ability of Mycobacterium tuberculosis to survive attacks from the host
immune response and drug treatment is due to the resilience of a few bacilli rather than a …

Model‐informed drug development for anti‐infectives: state of the art and future

CR Rayner, PF Smith, D Andes… - Clinical …, 2021 - Wiley Online Library
Model‐informed drug development (MIDD) has a long and rich history in infectious
diseases. This review describes foundational principles of translational anti‐infective …

A rabbit model to study antibiotic penetration at the site of infection for nontuberculous mycobacterial lung disease: macrolide case study

F Kaya, JP Ernest, K LoMauro… - Antimicrobial agents …, 2022 - Am Soc Microbiol
Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a potentially fatal infectious
disease requiring long treatment duration with multiple antibiotics and against which there is …

[HTML][HTML] Microfluidic dose–response platform to track the dynamics of drug response in single mycobacterial cells

M Mistretta, N Gangneux, G Manina - Scientific Reports, 2022 - nature.com
Preclinical analysis of drug efficacy is critical for drug development. However, conventional
bulk-cell assays statically assess the mean population behavior, lacking resolution on drug …

Emerging therapeutics, technologies, and drug development strategies to address patient nonadherence and improve tuberculosis treatment

M Garcia-Cremades, BP Solans… - Annual Review of …, 2022 - annualreviews.org
Imperfect medication adherence remains the biggest predictor of treatment failure for
patients with tuberculosis. Missed doses during treatment lead to relapse, tuberculosis …

Pivotal role of translation in anti‐infective development

LE Friberg - Clinical Pharmacology & Therapeutics, 2021 - Wiley Online Library
The value of model‐based translation in drug discovery and development is now effectively
being recognized in many disease areas and among various stakeholders. Such …

Development of predictive classification models for whole cell antimycobacterial activity of benzothiazinones

S Schieferdecker, FA Bernal, KP Wojtas… - Journal of Medicinal …, 2022 - ACS Publications
Nitrobenzothiazinones (BTZs) are a very potent class of antibiotics against Mycobacterium
tuberculosis. However, relationships between their structural properties and whole cell …